The FDA says state-licensed compounding pharmacies must immediately stop making compound versions of GLP-1 drugs. Larger, national licensed facilities making compound versions of Zepbound have until ...

GLP-1 drugs were also linked with better graft and patient survival in kidney transplant recipients with type 2 diabetes.

A federal judge has effectively ended the ability of compounding pharmacies to make their own copies of Eli Lilly’s weight ...

Eli Lilly & Co. said Tuesday it’s cutting the price of single-dose vials of its Zepbound treatment for diabetes and obesity for patients who have to pay for the drug themselves. It said it will ...

Back in December, I argued why I was ready to upgrade the stock of the embattled weight loss drugs leader Eli Lilly and Company (NYSE:LLY) even as it fell into a bear market after peaking in August.

Lilly is launching two new doses and cutting prices for self-paying customers Eli Lilly & Co. said Tuesday it's cutting the price of single-dose vials of its Zepbound treatment for diabetes and ...

Eli Lilly & Co. said Tuesday that it has launched new doses of its obesity treatment drug and reduced its prices. The pharmaceutical company said it has launched 7.5 and 10 milligram single-dose ...

Eli Lilly LLY-2.01%decrease; red down pointing triangle is expanding its offerings of its hit weight-loss drug Zepbound for people who want to pay cash instead of using their health plans ...

Drug company calls on insurers and federal programs to include coverage of obesity as a chronic disease Eli Lilly & Co. said Tuesday it's cutting the price of single-dose vials of its Zepbound ...

Eli Lilly released higher doses of its weight loss drug Zepbound in single-dose vials at as much as half its usual monthly list price to reach more patients without insurance coverage for the ...

Eli Lilly is unleashing new ammunition in its fight against cheaper, compounded versions of its obesity blockbuster Zepbound. The Indiana-based drugmaker is slashing the prices of its 2.5 mg ...